摘要
目的:探讨老年非小细胞肺癌(NSCLC)患者术后辅助化疗的无病生存益处及耐受性。方法:收集老年组113例、非老年组192例经过肺癌根治术的I-ⅢA期NSCLC患者的资料,对性别、年龄、病理诊断、分化程度、疾病分期、放化疗顺序、辅助化疗与否进行回顾性分析,以评估无病生存(DFS)期的预后因素。结果:两组接受术后辅助化疗后具有相似的无病生存期(P>0.05)。老年组接受术后辅助化疗比不化疗具有延长无病生存期的趋势,其中IIIA期患者具有统计学差异(P<0.05)。老年组与非老年组化疗后不良反应发生率相似,均可较好耐受。结论:老年NSCLC患者术后接受辅助化疗有延长无病生存的趋势,不良反应可以耐受。
Objective: To evaluate whether adjuvant chemotherapy prolongs disease -free survival among patients with completely resected early - stage non - small - cell lung cancer (NSCLC) in elderly patients and the toxicity and safety of the regimen. Methods: We retrospectively evaluated the clinicopathological features of the disease inclucling sex, age, pathological type, differentiation, stage, sequence of chemotherapy and radiotherapy, with or without adjuvant chemotherapy, to identify disease -free survival (DFS) prognostic factors. The clinical records of 113 patients aged 65 - year above and 192 patients aged 65 or 65 year below with stage Ⅰ - ⅢA NSCLC who underwent lobectomy or pneumonectomy with systematic lymph node dissection or sampling were retrospectively reviewed. Results: The DFS was similar in elderly and non - elderly NSCLC patients. There was a trend of prolonged DFS in adjuvant chemotherapy group , especially in stage ⅢA elderly patients ( P 〈 0. 05 ). The toxicity was similar in both elderly and non - elderly groups. Conclusion: Adjuvant chemotherapy has an acceptable level of toxicity and prolongs disease - free survival among elderly patients with completely resected early - stage non - small - cell lung cancer.
出处
《现代肿瘤医学》
CAS
2008年第10期1702-1704,共3页
Journal of Modern Oncology
关键词
老年患者
非小细胞肺癌
辅助化疗
无病生存期
elderly patients
non - small - cell lung cancer
adjuvant chemotherapy
disease - free survival